Kal Peterman
Nurse Practitioner · Honolulu, HINPI 1093480246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 24.1% of the total. Reporting peaked in 2023 at $533 and has fallen 87.1% since, to $69 in 2025.
Across 24 payments — averaging $29.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$169
- Mannkind Corporation$140
- Lilly USA, LLC$101
- Tandem Diabetes Care, Inc.$83
- Dexcom, Inc.$57
- Abbott$54
- plus $96 from 4 others
What the payments were for
- Food & beverage$700100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $169 |
| Mannkind Corporation | 3 | $140 |
| Lilly USA, LLC | 4 | $101 |
| Tandem Diabetes Care, Inc. | 2 | $83 |
| Dexcom, Inc. | 4 | $57 |
| Abbott | 3 | $54 |
| GSK | 2 | $36 |
| Medtronic | 1 | $21 |
| Amgen | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
How this compares
$700 in reported general payments places this provider in the 75th percentile of 215 nurse practitioner providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $220,269 |
| MounjaroTirzepatide | 74 | $120,344 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 41 | $99,449 |
| JardianceEmpagliflozin | 40 | $66,851 |
| TrulicityDulaglutide | 35 | $50,780 |
| ProliaDenosumab | 13 | $22,903 |
| KerendiaFinerenone | 11 | $13,092 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $10,545 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,764 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 45 | $4,418 |
| Novolog FlexpenInsulin Aspart | 15 | $3,865 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,479 |
| SynthroidLevothyroxine Sodium | 27 | $2,231 |
| Nateglinide | 20 | $1,992 |
| Atorvastatin Calcium | 51 | $1,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $169 | $220,269129 claims |
| Lilly USA, LLCMounjaro, Trulicity | $101 | $171,124109 claims |
| AmgenEvenity (2 Syringes), Prolia | $20 | $122,35254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 nurse practitioner providers in Hawaii.
Other nurse practitioner in Honolulu
- Ashley SpringerHonolulu$43K
- Sung JungHonolulu$29K
- Judy KoHonolulu$17K
- Bryce MontalboHonolulu$15K
- Rita AbreuHonolulu$9K
- Jinny ChingHonolulu$7K
- Nancy BanhHonolulu$6K
- Kelly FuruikeHonolulu$6K
- Qi ZhiHonolulu$5K
- Mio OsakiHonolulu$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.